SCOPUS 정보 검색 플랫폼

Volumn 61, Issue 6, 2001, Pages 2533-2536

Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: A cancer and leukemia group B study

(9) Bok, Robert A a Halabi, Susan d Fei, David T f Rodriquez, Carlos R f Hayes, Daniel F d Vogelzang, Nicholas J g Kantoff, Philip d Shuman, Marc A a Small, Eric J a

a UNIVERSITY OF CALIFORNIA (United States)

b CALGB Statistical Center (United States)

c DANA FARBER CANCER INSTITUTE (United States)

d Lombardi Cancer Center ^*

e GEORGETOWN UNIVERSITY (United States)

f GENENTECH INC (United States)

g UNIVERSITY OF CHICAGO MEDICAL CENTER (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR; SURAMIN; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN DETERMINATION; URINALYSIS;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; CLINICAL TRIALS, PHASE III; DRUG RESISTANCE, NEOPLASM; ENDOTHELIAL GROWTH FACTORS; FIBROBLAST GROWTH FACTOR 2; HUMANS; LYMPHOKINES; MALE; MIDDLE AGED; MULTICENTER STUDIES; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; SURAMIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0035866781 PISSN: 00085472 EISSN: None Source Type: Journal
DOI: None Document Type: Article

Times cited : (147)

References (23)

1
- 0027511899
- Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer
- (1993) J. Clin. Oncol. , vol.11 , pp. 607-615
- Kelly, W.K.¹ Scher, H.I.² Mazumdar, M.³ Vlamis, V.⁴ Schwartz, M.⁵ Fossa, S.D.⁶

2
- 0032784113
- Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 study
- (1999) J. Clin. Oncol. , vol.17 , pp. 2506-2513
- Kantoff, P.W.¹ Halabi, S.² Conaway, M.³ Picus, J.⁴ Kishner, J.⁵ Hars, V.⁶ Trump, D.⁷ Winer, E.P.⁸ Vogelzang, N.J.⁹

3
- 0032963468
- Prognostic indicators in hormone refractory prostate cancer
- (1999) Urol. Clin. N. Am. , vol.26 , pp. 303-310
- George, D.J.¹ Kantoff, P.W.²

4
- 0032907691
- A prognostic score for hormone-refractory prostate cancer: Analysis of two cancer and leukemia group B studies
- (1999) Clin. Cancer Res. , vol.5 , pp. 831-837
- Vollmer, R.T.¹ Kantoff, P.W.² Dawson, N.A.³ Vogelzang, N.J.⁴

5
- 0027502358
- Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients
- (1993) J. Natl. Cancer Inst. , vol.85 , pp. 241-242
- Nguyen, M.¹ Watanabe, H.² Budson, A.E.³ Richie, J.P.⁴ Folkman, J.⁵

6
- 0028328983
- Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers
- (1994) J. Natl. Cancer Inst. , vol.86 , pp. 356-361
- Nguyen, M.¹ Watanabe, H.² Budson, A.E.³ Richie, J.P.⁴ Hayes, D.F.⁵ Folkman, J.⁶

7
- 0032854988
- Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates
- (1999) J. Urol. , vol.161 , pp. 799-804
- Crew, J.P.¹ O'Brien, T.² Bicknell, R.³ Fuggle, S.⁴ Cranston, D.⁵ Harris, A.L.⁶

8
- 0032191768
- A sensitive fluorometric enzyme-linked immunosorbent assay that measures vascular endothelial growth factor-165 in human plasma
- (1998) J. Immunol. Methods , vol.219 , pp. 45-55
- Rodriguez, C.R.¹ Fei, D.T.² Keyt, B.³ Baly, D.L.⁴

9
- 0030334549
- Method selected for the determination of creatinine in plasma or serum. Choice of optimal conditions of measurement
- (1996) Ann. Biol. Clin. , vol.54 , pp. 285-298
- Labbé, D.¹ Vassault, A.² Cherruau, B.³ Baltassat, P.⁴ Bonète, R.⁵ Carroger, G.⁶ Costantini, A.⁷ Guérin, S.⁸ Houot, O.⁹ Lacour, B.¹⁰ Nicolas, A.¹¹ Thioulouse, E.¹² Trépo, D.¹³

10
- 33845382806
- Nonparametric estimation from incomplete observations
- (1958) J. Am. Stat. Assoc. , vol.53 , pp. 457-481
- Kaplan, E.L.¹ Meier, P.²

11
- 0000336139
- Regression models and life tables
- (1974) J. R. Stat. Soc. B. , vol.74 , pp. 187-220
- Cox, D.R.¹

12
- 0027162784
- Suramin: An anticancer drug with unique biological effects
- (1993) Cancer Chemother. Pharmacol. , vol.32 , pp. 96-98
- Larsen, A.K.¹

13
- 0030198685
- Suramin is a potent inhibitor of vacular endothelial growth factor. A contribution to the molecular basis of its antiangiogenic action
- (1996) J. Mol. Cell. Cardiol. , vol.28 , pp. 1523-1529
- Waltenberger, J.¹ Mayr, U.² Frank, H.³ Hombach, V.⁴

14
- 0033984872
- The significance of serum levels of insulin-like growth factor-1 in patients with prostate cancer
- (2000) BJU Int. , vol.85 , pp. 125-129
- Kurek, R.¹ Tunn, U.W.² Eckart, O.³ Aumüller, G.⁴ Wong, J.⁵ Renneberg, H.⁶

15
- 4243764268
- Scatter factor/hepatocyte growth factor as a serum marker for prostate cancer
- (2000) Proc. Am. Soc. Clin. Oncol. , vol.19 , pp. 338a
- Naughton, M.¹ Picus, J.² Zhu, X.³ Catalona, W.⁴ Vollmer, R.T.⁵ Humphrey, P.⁶

16
- 0032818964
- Plasma levels of vascular endothelial growth factor art increased in patients with metastatic prostate cancer
- (1999) Urology , vol.54 , pp. 523-527
- Duque, J.L.¹ Loughlin, K.R.² Adam, R.M.³ Kantoff, P.W.⁴ Zurakowski, D.⁵ Freeman, M.R.⁶

17
- 0033973345
- Elevated serum vascular endothelial growth factor in patients with hormone-escaped prostate cancer
- (2000) BJU Int. , vol.85 , pp. 276-280
- Jones, A.¹ Fujiyama, C.² Turner, K.³ Fuggle, S.⁴ Cranston, D.⁵ Bicknell, R.⁶ Harris, A.L.⁷

18
- 0004544462
- Vascular endothelial growth factor (VEGF) blond levels of patients with advanced solid tumors treated with chemotherapy are not related to treatment response
- (2000) Proc. Am. Assoc. Cancer Res. , vol.41 , pp. 308
- De Braud, F.G.¹ Sandri, M.T.² Zorzino, L.³ Locatelli, M.⁴ Masci, G.⁵ Rocca, A.⁶ Luco, F.⁷ Zamping, G.⁸

19
- 4244148459
- Circulating VEGF and FGF in patients with gastric carcinoma
- (2000) Proc. Am. Soc. Clin. Oncol. , vol.19 , pp. 267a
- Yoshikawa, T.¹ Tsuburaya, A.² Kobayashi, O.³ Sairenji, M.⁴ Motohashi, H.⁵ Yanoma, S.⁶ Noguchi, Y.⁷

20
- 0004565965
- CD31, vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) discriminate between subgroups of 827 patients-different angiogenic pathways in human breast cancer?
- (2000) Proc. Am. Soc. Clin. Oncol. , vol.19 , pp. 646a
- Linderholm, B.¹ Tavelin, B.² Grankvist, K.³ Henriksson, R.⁴

21
- 0033213978
- Tumor development under angiogenic signaling: A dynamical theory of tumor growth, treatment response, and postvascular dormancy
- (1999) Cancer Res. , vol.59 , pp. 4770-4775
- Hahnfeldt, P.¹ Panigrahy, D.² Folkman, J.³ Hlatky, L.⁴

22
- 0033530257
- Antiangiogenic activity of prostate-specific antigen
- (1999) J. Natl. Cancer Inst. , vol.91 , pp. 1635-1640
- Fortier, A.H.¹ Nelson, B.J.² Grella, D.K.³ Holaday, J.W.⁴

23
- 0034054325
- Target molecules for anti-angiogenic therapy: From basic research to clinical trials
- (2000) Crit. Rev. Oncol. Hematol. , vol.34 , pp. 89-110
- Hagedorn, M.¹ Bikfalvi, A.²

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.